CP and chronic myelogenous leukemia, BCR-ABL1 positive: Results from the previous analysis of this trial in patients with CML-CP without BCR::ABL1T315I after 4.2 years’ median exposure (cutoff, January 6, 2021) demonstrated continued MRs with long-term use; 53 patients (61.6%) achieved MMR and 48 of 53 maintained MMR or achieved deeper responses by the cutoff [16].